Glukagonoma Tanı ve Tedavi Yaklaşımları
Özet
Glukagonomalar, genellikle pankreasın distalinde yerleşen, glukagon salgılayan nadir ve fonksiyonel nöroendokrin tümörlerdir. Çoğunlukla sporadik olan bu tümörlerin %20'ye kadarı çoklu endokrin neoplazi sendromu tip 1 (MEN1) ile ilişkili olabilmektedir. Tanı anında genellikle büyük (>3 cm) ve %50 ila %80 oranında metastatiktirler. En belirgin klinik özellikleri arasında belirgin kilo kaybı, nekrolitik migratuar eritem (NME) adı verilen karakteristik cilt döküntüleri, glikoz intoleransı veya diyabet, normositik normokromik anemi ve ishal yer alır. Tanı, açlık plazma glukagon düzeyinin belirgin şekilde yüksek olmasının (>500 pg/mL) gösterilmesiyle konur. Tümörün lokalizasyonu ve evrelemesi için bilgisayarlı tomografi (BT), manyetik rezonans görüntüleme (MRG) veya somatostatin reseptör hedefli PET/BT gibi ileri görüntüleme yöntemlerinden yararlanılır. Tedavinin ilk basamağı destekleyici bakım ve hormon salgılanmasını baskılayarak semptomları kontrol altına alan somatostatin analoglarıdır. Lokalize vakalarda primer tümörün cerrahi rezeksiyonu tam kür şansı sunarken, ilerlemiş ve metastatik hastalıkta cerrahi debulking, hepatik arter embolizasyonu, ablasyon tedavileri, peptit reseptör radyoligand tedavisi (PRRT) ve sitotoksik kemoterapi gibi palyatif yöntemler uygulanır. Genellikle yavaş büyüyen tümörler olmalarına rağmen, tanı anında ileri evrede olmaları prognozu sınırlandırmakta; yaş, tümör derecesi ve uzak metastaz varlığı sağkalımın en önemli belirleyicileri olarak öne çıkmaktadır.
Glucagonomas are rare, functional neuroendocrine tumors that secrete glucagon, predominantly arising within the distal pancreas. Although most cases occur sporadically, up to 20% can be associated with Multiple Endocrine Neoplasia Type 1 (MEN1) syndrome. These tumors are typically large (>3 cm) at presentation, with 50% to 80% of patients already exhibiting metastatic disease, primarily in the liver, at the time of diagnosis. The clinical manifestation, known as glucagonoma syndrome, is characterized by significant weight loss, a distinct rash called necrolytic migratory erythema (NME), glucose intolerance or diabetes mellitus, normocytic normochromic anemia, and chronic diarrhea. Diagnosis is established by confirming inappropriately elevated fasting plasma glucagon levels (>500 pg/mL), while tumor localization and staging are achieved using contrast-enhanced CT, MRI, or somatostatin-receptor-targeted PET/CT imaging. Initial management focuses on supportive care and somatostatin analogs to inhibit hormonal secretion and alleviate systemic symptoms. Surgical resections offer a potential cure for localized tumors, whereas advanced or metastatic disease requires multimodal palliative strategies, including surgical debulking, hepatic artery embolization, radiofrequency or cryoablation, peptide receptor radionuclide therapy (PRRT), and cytotoxic chemotherapy. Despite their typically indolent growth pattern, the advanced stage at diagnosis often limits long-term survival, with patient age, tumor grade, and the extent of distant metastases serving as the primary prognostic determinants.
Referanslar
Klein S, Jahoor F, Baba H, et al. In vivo assessment of the metabolic alterations in glucagonoma syndrome. Metabolism 1992; 41:1171.
WHO Classification of Tumours. Digestive System Tumours, 5th ed, Klimstra DS, Kloppel G, La Rosa S, Rindi G, the WHO Classification of Tumours Editorial Board (Ed), the WHO classification of neuroendocrine neoplasms of the digestive system, p.16.
Wermers RA, Fatourechi V, Wynne AG, et al. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore) 1996; 75:53.
Song X, Zheng S, Yang G, et al. Glucagonoma and the glucagonoma syndrome. Oncol Lett 2018; 15:2749.
Eldor R, Glaser B, Fraenkel M, et al. Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour. Clin Endocrinol (Oxf) 2011; 74:593.
Wilkinson DS. Necrolytic migratory erythema with carcinoma of the pancreas. Trans St Johns Hosp Dermatol Soc 1973; 59:244.
Kitamura Y, Sato M, Hatamochi A, Yamazaki S. Necrolytic migratory erythema without glucagonoma associated with hepatitis B. Eur J Dermatol 2005; 15:49.
Kindmark H, Sundin A, Granberg D, et al. Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. Med Oncol 2007; 24:330.
de Mestier L, Hentic O, Cros J, et al. Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study. Ann Intern Med 2015; 162:682.
Lévy-Bohbot N, Merle C, Goudet P, et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol 2004; 28:1075.
Scarpa A, Chang DK, Nones K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 2017; 543:65.
Sundin A, Arnold R, Baudin E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology 2017; 105:212.
Deppen SA, Liu E, Blume JD, et al. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. J Nucl Med 2016; 57:708.
Sadowski SM, Neychev V, Millo C, et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol 2016; 34:588.
Dromain C, de Baere T, Baudin E, et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol 2003; 180:121.
Khashab MA, Yong E, Lennon AM, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc 2011; 73:691.
AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York Vol 2010, p.241.
Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011; 29:3044.
Bilimoria KY, Bentrem DJ, Merkow RP, et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007; 205:558.
Bergsland EK, Woltering EA, Rindo G. Neuroendocrine tumors of the pancreas. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.407. Corrected at 4th printing, 2018.
Boden G, Ryan IG, Eisenschmid BL, et al. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995. N Engl J Med 1986; 314:1686.
Smith AP, Doolas A, Staren ED. Rapid resolution of necrolytic migratory erythema after glucagonoma resection. J Surg Oncol 1996; 61:306.
Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford) 2010; 12:427.
Tran CG, Sherman SK, Chandrasekharan C, Howe JR. Surgical Management of Neuroendocrine Tumor Liver Metastases. Surg Oncol Clin N Am 2021; 30:39.
Cloyd JM, Ejaz A, Konda B, et al. Neuroendocrine liver metastases: a contemporary review of treatment strategies. Hepatobiliary Surg Nutr 2020; 9:440.
Qu Y, Li H, Wang X, et al. Clinical Characteristics and Management of Functional Pancreatic Neuroendocrine Neoplasms: A Single Institution 20-Year Experience with 286 Patients. Int J Endocrinol 2020; 2020:1030518.
Barat M, Cottereau AS, Kedra A, et al. The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review. J Clin Med 2020; 9.
Pickens RC, Sulzer JK, Passeri MJ, et al. Operative Microwave Ablation for the Multimodal Treatment of Neuroendocrine Liver Metastases. J Laparoendosc Adv Surg Tech A 2021; 31:917.
Radny P, Eigentler TK, Soennichsen K, et al. Metastatic glucagonoma: treatment with liver transplantation. J Am Acad Dermatol 2006; 54:344.
Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27:4656.
Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371:224.
Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:514.
Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501.
Makis W, McCann K, Riauka TA, McEwan AJ. Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy. Clin Nucl Med 2015; 40:877.
Zandee WT, Brabander T, Blažević A, et al. Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors. J Clin Endocrinol Metab 2019; 104:1336.
Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22:4762.
Nitter-Hauge S, Frøysaker T, Hall KV, Enge I. Influence of aorto-coronary saphenous vein bypass surgery on left ventricular function. Comparison before and one year after surgery in 80 patients. Scand J Thorac Cardiovasc Surg 1978; 12:241.
Cives M, Ghayouri M, Morse B, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer 2016; 23:759.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed on May 22, 2020).
